Prodrugs activated by plasmin and their use in cancer chemotherapy
US7402556B2 · kind B2 · utility
11Cited by
3References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2001 |
| Grant date | Jul 22, 2008 |
| Priority date | — |
| Expiry date | Nov 8, 2022 |
Classification
- Technology area (CPC B)Performing Operations; Transporting
- CPC primaryB82Y5/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.